Study to evaluate safety and efficacy of different doses of Bimekizumab in patients with chronic plaque psoriasis.

Registry ID

EUCTR2016-001891-31

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

UCB Biopharma SPRL

Start date

2016-10-27

Completion date

2017-07-10

Last update

2026-08-16

Conditions

• Chronic Plaque Psoriasis

Summary

Evaluate the dose response of Bimekizumab administered subcutaneously in subjects with moderate to severe chronic plaque psoriasis.

Locations

• , , Poland
• , , Hungary
• , , Czechia

Related clinical trials

• To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital

View on source registry